CD20 N-terminal, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-CD20 N-terminal, Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD20 N-terminal, Human |
| Clone | REAL1069 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | n/a |
| Format | phycoerythrin (PE) conjugate |
| Size | 200 µL |
| Concentration | n/a |
| Applications | MICS (MACSima Imaging Cyclic Staining), Immunohistochemistry, Immunofluorescence |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | CD20 N-terminal Antibody, anti-human, PE, REAdye_lease™. Clone REAL1069 is an antibody fragment derived from the full CD20 N-terminal antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity. | Clone REAL1069 recognizes the N-terminal region of the CD20 antigen. CD20 is a non-glycosylated transmembrane protein of 33-37 kDa that consists of four conserved transmembrane domains flanked by N- and C-terminal cytoplasmic domains. CD20 is expressed on B lineage cells from the pre-B cell stage to the B cell lymphoblast stage. The antigen is further expressed on most malignant B cells (B-cell lymphomas). CD20 is not found on early B cell progenitors or plasma cells. Oligomers of CD20 form a | Ca2+ channel and might function in the regulation of local responses during B cell activation. In vitro effects of CD20-specific antibodies on resting B cells indicate that CD20 is able to transduce an extracellular signal affecting the G0/G1 cell cycle transition. Studies have demonstrated that CD20-initiated intracellular signals involve tyrosine kinase activation and that CD20 is tightly associated with both serine and tyrosine kinases. | For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675). |
| Immunogen | n/a |
| Other Names | MS4A1, B1, Bp35, CVID5, LEU-16, MS4A2, S7, Ly-44 |
| Gene, Accession # | n/a |
| Catalog # | 130-127-404 |
| Price | $470 |
| Order / More Info | CD20 N-terminal, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Polyak, M. J. et al. (1998) Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J Immunol 161 (7): 3242-3248. | Mishima, Y. et al. (2011) The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations. Blood Cancer J. 1 (4): e15. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies